Antibodies that attack healthy proteins in the nucleus cells are called antinuclear antibodies. When a person has an autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus (SLE), the immune system produces antibodies that will attach to the cells, often causing damage to them. Some of the ANA tests are EUROPLUS ANA Mosaic 20A, QUANTA Lite ANA, BioPlex 2200 ANA Screen. The global ANA testing market is expected to benefit from the growing incidence of several autoimmune diseases worldwide.
MIR analysts forecast the global anti-nuclear antibody (ANA) testing market to grow at a CAGR of 7.13 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global anti-nuclear antibody (ANA) testing market for 2017-2021. To calculate the market size, the report considers the new installations/sales/volume/value and replacement/ services of anti-nuclear antibody testing market.
The market is divided into the following segments based on geography:
MIR report, Global Anti-Nuclear Antibody (ANA) Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
• Abbott Laboratories
• Bio-Rad Laboratories
• Thermo Fisher Scientific
Other prominent vendors
• Antibodies Incorporated
• Biocom Biotech
• Erba Diagnostics
• F. Hoffmann-La Roche
• HOB Diagnostics
• HUMAN Diagnostics
• Seramun Diagnostica
• Trinity Biotech
• Increased prevalence of autoimmune diseases
• For a full, detailed list, view our report
• Limitations of autoimmune disease diagnostics
• For a full, detailed list, view our report
• Shift from monoplex to multiplex testing
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
MIR recognizes the following companies as the key players in the global anti-nuclear antibody (ANA) testing market: Abbott Laboratories, Alere, Bio-Rad Laboratories, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Antibodies Incorporated, Biocom Biotech, Erba Diagnostics, F. Hoffmann-La Roche, HOB Diagnostics, HUMAN Diagnostics, IMMCO, ImmunArray, Phadia, Seramun Diagnostica, and Trinity Biotech.
Commenting on the report, an analyst from MIR team said: “The latest trend gaining momentum in the market is shift from monoplex to multiplex testing. The focus on multiplex testing is increasing, particularly in the area of IVD, owing to the increased need for effective diagnosis. Autoimmune diseases are chronic conditions that collectively affect around 5% to 8% of the US population. The individuals who develop organ-specific autoimmune disease have a high likelihood of developing additional autoimmune disorders. This has fueled the need for new technologies that can evaluate multiple immune reactivities in a small sample volume.”
According to the report, one of the major drivers for this market is increased prevalence of autoimmune diseases. Autoimmune diseases can affect any organ or system in the body, with the symptoms varying among disease types. There are about 80 types of autoimmune diseases in the world. Rheumatoid arthritis, Lupus, Celiac disease, and multiple sclerosis are some of the autoimmune diseases.
Further, the report states that one of the major factors hindering the growth of this market is limitations of autoimmune disease diagnostics. The limitations of autoimmune disease diagnostics in terms of key parameters such as accuracy pose a challenge to the market. The accuracy of autoimmune disease diagnostics determines the quality of results. Any discrepancy in this parameter will be unproductive to end-users, thereby impacting adoption rates. There are only a few tests that can potentially offer quality results. These tests allow rapid decision making and administration of suitable therapies for treating individuals with autoimmune diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
â¢ Market outline
PART 05: Market landscape
â¢ Market overview
â¢ Market size and forecast
â¢ Five forces analysis
PART 06: Market segmentation by end-user
â¢ Clinical diagnostic laboratories
PART 07: Geographical segmentation
â¢ ANA testing market in Americas
â¢ ANA testing market in EMEA
â¢ ANA testing market in APAC
PART 08: Decision framework
PART 09: Drivers and challenges
â¢ Market drivers
â¢ Market challenges
PART 10: Market trends
â¢ Shift from monoplex to multiplex testing
â¢ Collaborations between pharma and diagnostic companies
â¢ Growing consumer shift toward direct-to-consumer testing
PART 11: Vendor landscape
â¢ Competitive scenario
PART 12: Key vendor analysis
â¢ Abbott Laboratories
â¢ Bio-Rad Laboratories
â¢ Thermo Fisher Scientific
â¢ Other prominent vendors
PART 13: Appendix
â¢ List of abbreviations
List of Exhibits
Exhibit 01: Etiology of autoimmune diseases
Exhibit 02: Global ANA testing market 2016-2021: Market outline
Exhibit 03: Key trends in global autoimmune disease diagnostics market: Impact assessment
Exhibit 04: Global ANA testing market 2016-2021 ($ millions)
Exhibit 05: Five forces analysis
Exhibit 06: Global ANA testing market by end-users: Overview
Exhibit 07: Global ANA testing market by end-users: Impact assessment
Exhibit 08: Global ANA testing market by geography 2016 (%)
Exhibit 09: ANA testing market in Americas 2016-2021: Overview
Exhibit 10: ANA testing market in Americas 2016-2021 ($ millions)
Exhibit 11: ANA testing market in EMEA 2016-2021: Overview
Exhibit 12: ANA testing market in EMEA 2016-2021 ($ millions)
Exhibit 13: ANA testing market in APAC 2016-2021: Overview
Exhibit 14: ANA testing market in APAC 2016-2021 ($ millions)
Exhibit 15: Incidence estimates of type 1 diabetes, children aged 0â14 years, 2014
Exhibit 16: Key initiatives of vendors fueling the launch of novel biomarkers
Exhibit 17: Competitive structure analysis of global ANA testing market 2016
Exhibit 18: Competitive landscape analysis of global ANA testing market 2016
Exhibit 19: Strategic success factors of companies in global ANA testing market
Exhibit 20: Abbott Laboratories: Key highlights
Exhibit 21: Abbott Laboratories: Strength assessment
Exhibit 22: Abbott Laboratories: Strategy assessment
Exhibit 23: Abbott Laboratories: Opportunity assessment
Exhibit 24: Alere: Key highlights
Exhibit 25: Alere: Strength assessment
Exhibit 26: Alere: Strategy assessment
Exhibit 27: Alere: Opportunity assessment
Exhibit 28: Bio-Rad Laboratories: Key highlights
Exhibit 29: Bio-Rad Laboratories: Strength assessment
Exhibit 30: Bio-Rad Laboratories: Strategy assessment
Exhibit 31: Bio-Rad Laboratories: Opportunity assessment
Exhibit 32: Thermo Fisher Scientific: Key highlights
Exhibit 33: Thermo Fisher Scientific: Strategy assessment
Exhibit 34: Thermo Fisher Scientific: Strategy assessment
Exhibit 35: Thermo Fisher Scientific: Opportunity assessment
Companies Mentioned are -Abbott Laboratories, Alere, Bio-Rad Laboratories, Thermo Fisher Scientific, Antibodies Incorporated, Biocom Biotech, Erba Diagnostics, F. Hoffmann-La Roche, HOB Diagnostics, HUMAN Diagnostics, IMMCO, ImmunArray, Phadia, Seramun Diagnostica, and Trinity Biotech.
Research Methodology- Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.